Wealth Enhancement Advisory Services’s Pelthos Therapeutics PTHS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PTHS Stock Details PTHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,040	Closed	-$14.8K	–	3505
2025 Q1	$14.8K	Hold	1,040	–	–	﹤0.01%	2932
2024 Q4	$6.67K	Hold	1,040	–	–	﹤0.01%	2939
2024 Q3	$7.38K	Buy	+1,040	New	+$10.1K	﹤0.01%	2733

Other funds holding PTHS

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wealth Enhancement Advisory Services's PTHS Position: Q2 2025 in Review

Wealth Enhancement Advisory Services sold out of Pelthos Therapeutics (PTHS) in Q2 2025, closing a stake of 1,040 shares — an estimated $14.8K sold.

Wealth Enhancement Advisory Services first reported a position in PTHS in Q3 2024 and held it in 3 quarters. The position peaked at $14.8K in Q1 2025. 5 funds tracked by Wall St. Rank hold PTHS as of Q2 2025.

Wealth Enhancement Advisory Services reported no remaining Pelthos Therapeutics position as of Q2 2025 after selling out during the quarter.
Wealth Enhancement Advisory Services sold 1,040 Pelthos Therapeutics shares in Q2 2025, an estimated $14.8K.
Wealth Enhancement Advisory Services first reported a position in Pelthos Therapeutics in Q3 2024 and held it in 3 quarters.
Wealth Enhancement Advisory Services's Pelthos Therapeutics position peaked at $14.8K in Q1 2025.
5 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2025, filed 10 Jul 2025.